Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBUTEROL vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm,Off-label: Acute hyperkalemia (via nebulization)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
2.5 mg (0.5 m L of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life is 3.8-6.0 hours. In patients with asthma, the half-life is similar, but clinical effect duration is shorter due to rapid redistribution from the receptor site.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily metabolized via sulfotransferase (SULT1A3) to inactive sulfate conjugate; minor hepatic metabolism by CYP450 enzymes.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily renal: approximately 60-70% of the dose is excreted in urine as unchanged drug and metabolites (sulfate conjugate) within 24 hours. Fecal excretion accounts for less than 10%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 52-65% bound to human serum albumin and alpha-1-acid glycoprotein.
55–65% bound to plasma proteins, primarily albumin.
Approximately 1.4-2.0 L/kg. This relatively large Vd indicates extensive distribution into tissues, including lung parenchyma.
0.4–0.6 L/kg, indicating distribution into total body water.
Inhaled: 10-20% of the dose reaches the lungs systemically; Oral: approximately 28-40% (due to first-pass metabolism to sulfate conjugate); Subcutaneous: nearly 100%.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No dosage adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No specific guidelines; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Nebulized: 0.05-0.15 mg/kg/dose (minimum 1.25 mg) every 4-6 hours as needed. MDI: 1-2 inhalations (90 mcg/inhalation) every 4-6 hours as needed. Maximum: 12 inhalations/day.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Initiate at lower end of dosing range; monitor for tremors, tachycardia, and hypertension. No specific dose adjustment required.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None.
No FDA black box warning exists for this drug.
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects: increased heart rate, hypertension, arrhythmias,Hypokalemia may occur with high doses,Immediate hypersensitivity reactions possible,Use caution in patients with cardiovascular disorders, hyperthyroidism, diabetes, or seizure disorders
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to albuterol or any component of the formulation
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
No clinically significant food interactions. Caffeine may potentiate stimulant effects; avoid excessive caffeine intake.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
FDA Pregnancy Category C. In first trimester, no increased risk of major congenital anomalies based on human data. Second and third trimesters: risk of maternal tachycardia, hyperglycemia; fetal tachycardia, hypoglycemia at birth if used near term. Possible association with gastroschisis in first trimester from some studies, but not confirmed.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Excreted into breast milk in low concentrations; M/P ratio not established. Limited data suggest no adverse effects in infants. American Academy of Pediatrics considers compatible with breastfeeding. Use with caution in preterm infants or those with tachycardia.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No specific dose adjustment required for pregnancy. Pharmacokinetics may be altered due to increased plasma volume and renal clearance, but clinical significance is minimal. Use lowest effective dose to control symptoms.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Monitor for paradoxical bronchospasm; use with caution in patients with cardiovascular disorders due to beta-adrenergic stimulation; may cause hypokalemia with high doses; combine with ipratropium for acute exacerbations; not recommended for long-term control without anti-inflammatory therapy.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Use only as prescribed; do not exceed recommended dose.,Rinse mouth after use to prevent oral candidiasis (if using with corticosteroid), but albuterol alone does not require rinsing.,Seek emergency care if symptoms worsen or inhaler provides less relief.,Shake inhaler well before each use; use spacer if available for better delivery.,Monitor for palpitations, tremors, or nervousness; report if severe.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBUTEROL vs AEROLATE SR, answered by our medical review team.
ALBUTEROL is a Beta-2 Adrenergic Agonist (Bronchodilator) that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP, leading to bronchodilation.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBUTEROL and AEROLATE SR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBUTEROL is: 2.5 mg (0.5 m L of 0.5% solution) via nebulization every 4-6 hours as needed; or 1-2 inhalations (90 mcg/inhalation) from a metered-dose inhaler every 4-6 hours as needed.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBUTEROL and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBUTEROL is classified as Category C. FDA Pregnancy Category C. In first trimester, no increased risk of major congenital anomalies based on human data. Second and third trimesters: risk of maternal tachycardia, hyperg. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.